Table 1.
Patient characteristics at diagnosis (n = 231)
| Characteristics | n | % |
|---|---|---|
| Age (years), n = 231 | ||
| Median (range) | 59 (26–80) | |
| Treatment period, n = 231 | ||
| 1999–2002 | 100 | 43 |
| 2002–2007 | 131 | 57 |
| Tumor stage, n = 231 | ||
| I | 87 | 38 |
| II | 22 | 9 |
| IIIA | 120 | 52 |
| IIIB | 2 | 1 |
| Histological grade, n = 225 | ||
| I | 37 | 17 |
| II | 118 | 52 |
| III | 70 | 31 |
| Lymph node involvement, n = 231 | ||
| 0 | 98 | 42 |
| 1–3 | 99 | 43 |
| 4–9 | 27 | 12 |
| ≥10 | 7 | 3 |
| Receptor expression status | ||
| ER+, n = 229 | 176 | 77 |
| PR+, n = 226 | 147 | 65 |
| ER+ or PR+, n = 226 | 187 | 83 |
| HER2+, n = 194 | 96 | 49 |
| Triple negative (ER−, PR−, HER2−), n = 192 | 14 | 7 |
| Menopausal status, n = 230 | ||
| Pre-/perimenopausal | 101 | 44 |
| Postmenopausal | 129 | 56 |
| Hormonal treatment and related agents, n = 231 | ||
| Yes | 188 | 81 |
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2